OptimizeRx Corporation (OPRX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
OPRX Revenue Growth
OPRX Revenue Analysis (2014–2025)
As of May 8, 2026, OptimizeRx Corporation (OPRX) generated trailing twelve-month (TTM) revenue of $109.4 million, reflecting slight decline in growth of -0.2% year-over-year. The most recent quarter (Q4 2025) recorded $32.2 million in revenue, up 23.7% sequentially.
Looking at the longer-term picture, OPRX's 5-year compound annual growth rate (CAGR) stands at +20.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $109.4 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including HCAT (+1.5% YoY), DOCS (+15.9% YoY), and PRVA (+24.7% YoY), OPRX has underperformed the peer group in terms of revenue growth. Compare OPRX vs HCAT →
OPRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| OPRXCurrent | $109M | -0.2% | +20.4% | 10.7% | |
 HCAT | $311M | +1.5% | +10.5% | -51.7% | |
 DOCS | $570M | +15.9% | +37.4% | 39.9% | |
 PRVA | $2.1B | +24.7% | +21.0% | 1.6% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 PGNY | $1.3B | +6.6% | +30.2% | 6.6% |
OPRX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $109.4M | +18.8% | $73.6M | 67.3% | $11.7M | 10.7% |
| 2024 | $92.1M | +28.8% | $59.4M | 64.5% | $-13,706,000 | -14.9% |
| 2023 | $71.5M | +14.5% | $42.9M | 60.0% | $-26,402,000 | -36.9% |
| 2022 | $62.5M | +1.9% | $39.0M | 62.4% | $-12,290,738 | -19.7% |
| 2021 | $61.3M | +41.5% | $35.6M | 58.1% | $361K | 0.6% |
| 2020 | $43.3M | +76.1% | $24.1M | 55.7% | $-2,135,319 | -4.9% |
| 2019 | $24.6M | +16.0% | $15.4M | 62.8% | $-3,693,564 | -15.0% |
| 2018 | $21.2M | +74.9% | $12.2M | 57.6% | $180K | 0.8% |
| 2017 | $12.1M | +56.5% | $6.0M | 49.1% | $-2,129,966 | -17.6% |
| 2016 | $7.8M | +7.4% | $4.3M | 56.0% | $-1,581,512 | -20.4% |
See OPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OPRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OPRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonOPRX — Frequently Asked Questions
Quick answers to the most common questions about buying OPRX stock.
Is OPRX's revenue growth accelerating or slowing?
OPRX revenue growth slowed to -0.2%, below the 5-year CAGR of +20.4%. TTM revenue is $109M. The deceleration marks a shift from historical growth rates.
What is OPRX's long-term revenue growth rate?
OptimizeRx Corporation's 5-year revenue CAGR of +20.4% reflects the variable expansion pattern. Current YoY growth of -0.2% is near this long-term average.
How is OPRX's revenue distributed by segment?
OPRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.